Sandoz in the news

Healthcare stocks, including Sandoz, Roche, and Galderma, experienced a temporary weakness due to an analyst downgrade, while Roche acquired SAGA Diagnostics and Barry Callebaut faced multiple analyst downgrades.

Sandoz is reducing its workforce by about 100 employees in its generic medicine development center in Kundl, Austria, while maintaining antibiotic production.

Sandoz entered a supply agreement with the Rwandan government for approximately 60 products, aiming to provide affordable medicines to Rwanda and other African nations.

Sandoz is closing a Thyronine production line in Langkampfen/Schaftenau and its Development Center in Kundl, leading to job reductions due to economic non-viability and a need for competitiveness.

Berenberg raised its price target for Sandoz, viewing 2026 as a crucial implementation year, alongside positive financial and ESG ratings.

Gilbert Ghostine has led Sandoz for three years and will soon become president of SGS, detailing his career and motivations.

Sandoz partnered with Samsung Bioepis to develop and market up to five biosimilars, expanding its pipeline and targeting a large biosimilar market.

Sandoz Group collaborates with Samsung Bioepis to develop biosimilar medicines, enhancing affordable healthcare options.

Sandoz is ceasing the production of a hormone basic substance in Schaftenau, leading to the dismantling of facilities and affecting around 30 jobs.

The document discusses Sandoz Group Ltd's total debt per share on the SIX exchange.

Gilbert Ghostine, the head of Sandoz, is set to become the president of SGS.

Sandoz focuses its generic and biosimilar drug production and significant investments in Slovenia, leveraging local expertise and cost advantages despite its Swiss branding.

Sandoz partners with Samsung Bioepis to develop and market up to five biosimilars, expanding its biosimilar portfolio and market reach globally except in some Asian countries.

Sandoz issued CHF 550 million in dual-tranche bonds for general corporate use, advised legally by Advestra.

Sandoz and the Rwandan government signed an agreement for Sandoz to directly supply critical medicines, including antibiotics and cancer therapies, to Rwanda and other African nations.

Sandoz saw strong 2025 growth in revenue, profits, and biosimilars sales despite challenges from US tariffs impacting antibiotic raw materials.

Sandoz confirmed strong 2025 results with 7% revenue growth, ahead of biosimilar targets, and expects further profitability and growth driven by expiring biologic patents and new generics.

Sandoz slightly surpassed revenue estimates and significantly exceeded profit expectations, driven by strong generics sales.

Gilbert Ghostine, soon to be Swiss citizen and Sandoz president, expresses optimism about the global economy despite challenges.

Sandoz is closing its Development Center in Kundl, Austria, cutting about 100 jobs, while retaining antibiotic production and investing in the site.